97 results about "Aspartate transaminase" patented technology

The invention provides a stable composition containing NAD+ or NADH. Bioactivity of NAD+ or NADH can be stably maintained for a long time. By the use of a stabilizer which contains trehalose, glycerol, a buffer solution and a surfactant, stability of NAD+ and NADH dissolved state is raised. The invention also provides a method for stabilizing NAD+ or NADH, and also provides an application of a composition composed of trehalose, glycerol, the buffer solution, the surfactant and a pH regulator in increasing stability of NAD+ or NADH. The composition can be used for a lactate dehydrogenase reagent, an alanine aminotransferase reagent, an aspartate aminotransferase reagent, a urea kid and the like, and is widely applied.

The present invention relates to a compound of Antrodia camphorata used for liver protection, in particular to an extract, 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone which is isolated from Antrodia camphorata. The cyclohexenone compound according to the invention helps to alleviate liver injury and fibrosis induced by chemicals and reduces the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). By increasing the contents of glutathione peroxidase (GSHPx) and catalase (CAT), cyclohexenone further decreases the liver damage and the oxidative pressure caused by free radicals, enhances the antioxidant ability and achieves the purposed of liver protection.

Disclosed is a strain of Escherichia sp., capable of producing O-acetyl homoserine in high yield, with the introduction and enhancement therein of the activity of: homoserine acetyl transferase, aspartokinase and homoserine dehydrogenase; and at least one enzyme selected from a group consisting of phosphoenolpyruvate carboxylase, aspartate aminotransferase and aspartate semi-aldehyde dehydrogenase. Also, a method of producing O-acetyl homoserine using the strain is provided.

The invention discloses hepatic fibrosis detection system, relating to the technical field of hepatic fibrosis research. The hepatic fibrosis detection system comprises a transient elastography device an input device, a classifier and an output device, wherein the input device is used for receiving ages and serum biochemical indicators, and the serum biochemical indicators at least comprise blood platelet, hyaluronic acid (HA), serum direct bilirubin (DBIL), prothrombin time (PT), alanine aminotransferase / serum glutamic pyruvic transaminase (ALT; GPT), and aspartate transaminase / serum glutamic oxalacetic transaminase (AST; GOT); the classifier is used for performing hepatic fibrosis staging according to the ages and the serum biochemical indicators and received by the input device and transient elasticity imaging data; and the output device is used for outputting of hepatic fibrosis staging results of the classifier. The hepatic fibrosis detection system of the embodiment disclosed by the invention has the advantages of noninvasiveness, strong practicability, simple and convenient method, low price, good safety and the like.

Provided is a pharmaceutical or food or drink composition for preventing or treating alcohol-induced fatty liver or steatohepatitis comprising metadoxine (pyridoxol 1-2-pyrrolidone-5-carboxylate) and garlic oil as active ingredients. The concurrent administration of metadoxine and garlic oil according to the present invention exhibits outstandingly superior effects of inhibiting the accumulation of triglyceride and increase of blood AST (aspartate aminotransferase) level in liver el tissue, inhibiting the expression of FAS (fatty acid synthase), CYP2E1 and iNOS (inducible nitric oxide synthase) and inhibiting the deactivation of AMPK (AMP-activated protein kinase), as compared to the administration of metadoxine or garlic oil only.

The invention discloses a Chinese date leaf extractive and an application thereof in preparation of a medicament or health food for preventing and treating liver injury. The way that macroporous resin is coupled with polyamide resin and then a fine Chinese date leaf extractive is prepared through a preparative liquid phase is firstly adopted; compared with the traditional separation and purification method, the way has the advantages that the separation efficiency is higher, the active component obtained through separation is higher in content, strong in biological activity and high in safety. Experiment researches show that the Chinese date leaf extractive can be used for remarkably reducing the activities of ALT (Alanine Transaminase) and AST (Aspartate Transaminase) in serum of a model mouse with liver injury caused by CCl4, D-GalN and ethanol and the content of MDA (Methyl Di Aldehyde) in liver tissues and enhancing the activity of SOD (Superoxide Dismutase) of the liver and has favorable preventing and treating effects. Therefore, Chinese date leaves and the Chinese date leaf extractive are expected to be developed into a new-generation safe and effective medicament or health food for preventing and treating liver injury, and meanwhile, an approach is also provided for turning the waste Chinese date leaf resource into the things of value and comprehensively utilizing a date tree resource.

Disclosed is a strain of Escherichia sp., capable of producing O-acetyl homoserine in high yield, with the introduction and enhancement therein of the activity of: homoserine acetyl transferase, aspartokinase and homoserine dehydrogenase; and at least one enzyme selected from a group consisting of phosphoenolpyruvate carboxylase, aspartate aminotransferase and aspartate semi-aldehyde dehydrogenase. Also, a method of producing O-acetyl homoserine using the strain is provided.

The invention discloses a preparation method of quality control serum for quality control of centrifugal microfluidic chips. The method comprises the following steps: adding 0.6 to 1.0 percent of cholesteryl sodium sulfate into bovine plasma, and adding 0.02 to 0.06 percent of monopotassium phosphate; sequentially adding 0.04 to 0. 08 percent of ammonium ferric sulfate dodecahydrate, 0.5 to 0.9 percent of calcium chloride, 0.2 to 0.6 percent of bitter salt, 0.6 to 1 percent of urea, 9 to 13 percent of sodium chloride, 0.01 to 0.03 percent of zinc vitriol, 0.01 to 0.03 percent of chalcanthite,0.06 to 0.2 percent of glycocholic acid, 2 to 4 percent of glucose, 0.03 to 0.06 percent of creatinine, 0.08 to 0.2 percent of uric acid, and 0.07 to 0.11 percent of triolein into water; uniformly mixing obtained solution; adding glycol, saccharose and triton X-100, and uniformly mixing; sequentially adding albumin bovine serum, sodium azide, alanine aminotransferase, aspartic transaminase, alkaline phosphatase, lipase and creatine kinase, uniformly mixing, and performing freeze drying. The method has the advantages that the source of the raw materials is sufficient, the raw materials are easyto get, possible matrix effect is furthest avoided, and precipitation of the raw materials is prevented.

The present invention relates to a compound of Antrodia camphorata used for liver protection, in particular to an extract, 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone which is isolated from Antrodia camphorate. The cyclohexenone compound according to the invention helps to alleviate liver injury and fibrosis induced by chemicals and reduces the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). By increasing the contents of glutathione peroxidase (GSHPX) and catalase (CAT), cyclohexenone further decreases the liver damage and the oxidative pressure caused by free radicals, enhances the antioxidant ability and achieves the purposed of liver protection.

The invention belongs to the field of molecular immunology, and in particular relates to an exosome secreted and released from the epidermal cells of a chicken liver, gall bladder and bile duct, and a preparation method of the exosome. The exosome contains hepatogenic proteins, such as C-reactive protein, aspartate aminotransferase, and vitronectin, epithelium-derived mucin and proteins related to an immune reaction, such as immunoglobulin, and can be taken as a biological indicator for studying liver diseases and as an adjuvant for immune reaction for immune-regulation, and can also be takenas a carrier for treating the diseases of livers, gall bladders and intestines.

The invention discloses an aspartate transaminase mitochondrial isozyme detection kit, comprising: reagents 1: 0.02-0.5mol / L of buffer solution of which pH value is 6.5-8.0, 0.15-0.3mol / L of L-potassium aspartate, 0.3-5KU / L of malic dehydrogenase, 0.3-5KU / L of lactic dehydrogenase, 5-20mL / L of human cAST antibody, 0.01-3% of antibody stabilizer, 0.01-10% of enzyme stabilizer and 0.01-1% of preservative; and reagents 2: 0.02-0.5mol / L of buffer solution of which pH value is 7.0-9.0, 0.005-0.02mol / L of alpha-ketoglutarate, 0.1-0.5mmol / L of reduced coenzyme I, 0.01-1% of preservative and 0.01-10% of reduced coenzyme I stabilizer. The kit has the advantage of good stability.

The invention provides a compound microorganism beverage. The compound microorganism beverage has the advantages that the content of compound microorganisms is high, the activity is high, the stability is high, the action effect is quick, any side effect is avoided, the storage time is long, and the obvious liver protecting and hangover alleviating effects are realized. The compound microorganismbeverage is prepared by mixing the following raw materials in parts by weight: 30 to 40 parts of bacillus subtilis fermenting solution, 30 to 40 parts of thiocapsa roseopersicina fermenting solution,and 30 to 40 parts of rhizopus oryzae fermenting solution. The compound microorganism beverage has the advantages that the selected bacteria are screened by the hangover alleviating and ethyl alcoholretention rate test; higher ethyl alcohol retention rate can inhibit the absorbing of ethyl alcohol by gastrointestinal tract, and accelerate the metabolism of ethyl alcohol in stomach, and then the concentration of ethyl alcohol in blood is reduced; the compound microorganism beverage contains rich polyglutamic acid, polypeptide, polysaccharide and probiotics, so that the levels of ALT (alanine transaminase) and AST (aspartate transaminase) in serum are effectively reduced, the alcoholic liver injury is prevented and treated, and the liver injury is reduced by improving the anti-oxidizing ability of liver.

The invention relates to traditional Chinese medicine composition with functions of relieving alcoholism and protecting the liver. The traditional Chinese medicine composition comprises raw medicinalmaterials as follows: flos puerariae, semen hoveniae, medicated leaven, fructus amomi rotundus, white poria cocos, radix ginseng, raw fructus crataegi, fructus schisandrae chinensis and raw oysters, and the raw medicinal materials are compatible and have the functions of eliminating dampness caused by alcohol and regulating qi-flowing for strengthening spleen. The pharmacological experiment indicates that with the adoption of the traditional Chinese medicine composition, drunkenness latency time of a mouse can be prolonged, drunkenness time of the mouse is shortened, content of alcohol in blood is reduced, level of ALT (alanine aminotransferase), AST (aspartate aminotransferase) and MDA (malondialdehyde) in the liver is reduced, activity of GSH-PX (glutathione peroxidase) and ADH (alcoholdehydrogenase) is improved, and the traditional Chinese medicine composition has excellent effects of relieving alcoholism and protecting the liver.

The invention provides edible vinegar / vinegar paste prepared by utilizing vintage wine yeast micropopulation. The edible vinegar / vinegar paste is brewed by micropopulation of vintage wine yeast, free amino acid total content is 0.403-0.835mg / g, arginine content should be greater than 0.034mg / g, valine content is greater than 0.033mg / g, and aspartic acid content is greater than 0.026mg / g. The edible vinegar / vinegar paste can be used for preparing drug or healthcare products for lowering alanine transaminase (ALT), aspartate transaminase (AST), total cholesterol (TC) triglyceride (TG) and uric acid (UA) and protecting liver. The invention further provides a method of utilizing the vintage wine yeast micropopulation to prepare the edible vinegar / vinegar paste.

The invention discloses an application of a mulberry polysaccharide extract in preparing a medicine or a health product capable of preventing or inhibiting chemical liver injury. The mulberry polysaccharide extract has relatively wide biological activity and high activity, and can obviously reduce the levels of alanine aminotransferase and aspartate transaminase in serum, effectively improve the activities of superoxide dismutase and glutathion peroxidase in the liver, and obviously reduce the content of glutathione and malonaldehyde. The mulberry polysaccharide extract can be used for preparing a medicine or a health product, in particular for preparing the medicine or the health product having an inhibiting or preventing effect for the chemical liver injury.

The invention is applicable to the field of Chinese patent medicines. A lipopolysaccharide-induced rat diffuse intravascular coagulation model is adopted for experimenting, and the experiment result shows that a compound thrombosis capsule can significantly inhibit the rise of liver-function biochemical indexes of aspartate aminotransferase and alanine aminotransferase, reduces the level of lipopolysaccharide-induced liver inflammation, and reduces congestion and hemorrhage phenomena in liver veins, namely finding out the new application of the compound thrombosis capsule playing a role of protecting the liver.

The invention relates to a method for producing sea cucumber bio-alcohol. The method has the following characteristics that: sea cucumber is soaked in water, the produced soak is centrifugally filtered and concentrated, the produced concentrated solution is cooled, fucoidan hydrolytic enzyme is added to enzymatically hydrolyze the fucoidan in the concentrated solution, the temperature is increased to 80 DEG C to 90 DEG C, so that the fucoidan hydrolytic enzyme is inactivated, the produced enzymatically hydrolyzed solution is filtered, edible alcohol and auxiliary materials are added and blended, and the produced sea cucumber bio-alcohol is filtered by diatomite, filled, sterilized and packed. The sea cucumber bio-alcohol can increase the pH value of the acidic body fluid of the human body, enhance the activity of insulin, repair islet cells injured by the acidic constitution, recover the normal functions of islet cells and effectively reduce postprandial plasma glucose; and the sea cucumber bio-alcohol can strengthen metabolism, improve the acidic constitution, stabilize blood pressure, reduce blood sugar, blood fat, blood viscosity and the like, prevent and improve diabetes complication, notably reduce the activity of liver-injuring serum alanine aminotransferase and aspartate aminotransferase, increase the activity of liver SOD and reduce the content of MDA, thus having the function of protecting the liver.

The invention discloses a composite stabilizer for an aspartate aminotransferase assay kit. The composite stabilizer comprises trihydroxymethyl aminomethane, disodium ethylenediaminetetraacetate, trehalose, gelatin, propylene glycol, a surfactant Brij-35 and a liquid biological preservative Proclin300. Through the technical scheme, the composite stabilizer for the aspartate aminotransferase assay kit comprises the components of a buffer solution, a stabilizer, a chelating agent, an organic solvent, a surfactant and a preservative and the like. After the composite stabilizer is added into the aspartate aminotransferase assay kit in a certain volume ratio, not only the accuracy of an assay result can be ensured, but also the stability thereof is higher, and the expiry date after the aspartate aminotransferase assay kit is opened can be effectively prolonged.

The invention provides an application of GGPPS serving as a target for treating non-alcoholic fatty liver disease. A GGPPS antagonist disclosed by the invention can reduce genetic expression related to lipid accumulation of the liver. The liver-specific knockout GGPPS disclosed by the invention is capable of retarding the lipid accumulation and degeneration of the liver, reducing the level of aspartate transaminase (AST) and alanine aminotransferase (ALT) and protecting the liver functions.

The invention relates to a reagent for the quantitative determination of mitochondrial AST (Aspartate Aminotransferase) activity in human serum. The reagent comprises a reagent I and a reagent II which are placed separately, wherein the reagent I contains Tris buffer, L-aspartic acid, malate dehydrogenase, lactate dehydrogenase, a c-AST goat anti-human antibody and an enzyme stabilizer; the reagent II contains alpha-ketoglutaric acid and reductive coenzyme. A kit and a detection method adopted in the invention only require tens of microlitres of serum, need no centrifugation or electrophoresis and other separation treatments, are easy to operate, can meet the requirements of automatic analysis, and are applicable to the timely and accurate detection of large-scale samples.

The invention discloses recombinant escherichia coli for producing melatonin, and a construction method and application of the recombinant escherichia coli. The invention first discloses the recombinant escherichia coli, and compared with receptor escherichia coli, the recombinant escherichia coli has the advantages that the expression amount of a gene of a melatonin biosynthesis-related protein is increased, and / or the content of the melatonin biosynthesis-related protein is increased, and / or activity of the melatonin biosynthesis-related protein is increased, wherein the melatonin is selected from at least one of phenylalanine hydroxylase, dihydromonophosphate reductase, 4alpha-hydroxytetrahydrobiopterin dehydratase, aspartate transaminase family protein, N-acetyltransferase and caffeicacid-O-methyltransferase.and further discloses a construction method and application of the recombinant escherichia coli. The recombinant escherichia coli strain for producing melatonin has melatoninsynthesis efficiency is obviously higher than other existing strains, and has great significance for industrial production and large-scale application of melatonin.

The invention relates to a stable kit for diagnostically detecting aspartate aminotransferase; the kit finishes detection by using a composite stabilizer instead of a previous independent stabilizer; the composite stabilizer is a novel efficient stabilizer and may have a different composition for a different biochemical reagent, but is important to protecting related enzymes in reagents; the stabilizer acts mainly in the following way: the composite stabilizer forms a spherical film under certain solute and external conditions, and the spherical film may wrap organic enzymes and release the enzymes for reaction in the case of substrate induction; a direction is provided for processing and improving instability factors of biochemical reaction that the enzymes in biochemical reagents engage in, and basis is laid for the marketing and long-term development of the kit.

The invention belongs to the technical field of Chinese traditional medicine application, and specifically relates to application of chrysin to preparation of drugs for treating obesity-related metabolically triggered inflammations. According to the invention, the chrysin promotes the replacement activation of IL-4 activated mouse macrophages, promotes the release of anti-inflammatory cytokines IL-10, and promotes the rise of enzyme activity of typical labeled molecule arginine for the replacement activation of the macrophages, the up-regulation of surface molecules MGL1 / 2 and the up-regulation of classical molecules CD206, Ym1 and Fizz. Especially, in fat mice C57 / B6 induced by high-fat feeding, the chrysin is capable of inhibiting the release of proinflammatory cytokines TNF-alpha, AST (Aspartate Transaminase) and ALT (Alanine Transferase) in blood serum, increasing the release of the anti-inflammatory cytokines IL-10, alleviating the lesion of liver and adipose tissues, inhibiting the phagocytic function of the peritoneal macrophages, the antigen presentation ability and the release ability of NO, and lowering the expression of the typically activated surface molecules CCR7 and CD80 of the macrophages. According to the invention, a new drug for treating the obesity-related metabolically triggered inflammations is developed.

The invention discloses application of a chitosan oligosaccharide (COSM) with the molecular weight not higher than 3000 to preparing a drug-induced liver injury protecting and treating composition, particularly a composition for protecting and treating acetaminophen-induced liver injury. The invention also discloses a drug-induced liver injury protecting and treating method. The drug-induced liverinjury protecting and treating method comprises providing a liver injury patient with an effective quantity of the COSM. Experiments prove that the COSM can adjust acetaminophen-induced abnormity ofliver function biochemical indexes, significantly reduce abnormal rise of ALT (alanine transaminase) and AST (aspartate transaminase) in mice serum, improve acetaminophen-induced liver injury, improvethe content of a detoxicant of glutathione (GSH) in acetaminophen-induced liver injury-affected liver tissues, enhance the oxidation resistance of acetaminophen-induced oxidative injury-affected liver and reduce the content of malondialdehyde (MDA) of acetaminophen-induced liver oxidative injury. The COSM is expected to be developed and applied to treating liver injury caused by clinical treatment drugs and provide a better choice for patients.

IL1A or a gene located near IL1A on chromosome 2q14 may contribute to hepatotoxicity, as measured by increased serum levels of aspartate transaminase, during N-benzoyl-staurosporine treatment for macular edema. Accordingly, genetic polymorphisms in the IL1A gene are useful as biomarkers for predicting staurosporine derivative-mediated hepatotoxicity.

The invention relates to a model and a system for predicting severe new coronal pneumonia as well as an establishment method and a prediction method of the model and the system, and the prediction model is a progression risk score calculation model obtained according to lung diseases, age, immune globulin M (IgM), CD16 + / CD56 + NK cells and aspartate transaminase (AST) of a patient with new coronal pneumonia so as to predict the risk of progressing from mild / ordinary type to severe new coronal pneumonia. According to the invention, light / ordinary patients with high development risk can be identified, and the diagnosis and treatment success rate of critical patients can be improved.

The invention discloses application of monomeric compounds of fruits of Chinese magnoliavine (Schisandra chinensis(Turcz.) baill. and Schisandra sphenanthera Rehd.et Wils) to preparation of medicine for preventing and treating cholestasis liver diseases. The monomeric compounds of fruits of Chinese magnoliavine refer to Schisandrin B, Schisandrin C, Schisandrol A, Schisantherrin A and Schisantherrin B. The result of the study shows that all of the five kinds of monomeric compounds can obviously reduce the content of total bile acids and direct bilirubin in blood serum in the cholestasis liverdisease state, can relieve the cholestasis symptoms, can reduce the activity of alkaline phosphatase, gamma-glutamyltransferase, aspartate transaminase and / or alanine aminotransferase in the liver, and can effectively improve the liver tissue necrosis degree. The invention discovers the condition for the first time that the five kinds of monomeric compounds of fruits of Chinese magnoliavine can beused for effectively preventing and treating the cholestasis liver diseases induced by liithocholic acid. The discovery provides the powerful technical theoretical basis for the new medicine researchand development for the cholestasis liver diseases and the clinic application of the monomeric compounds of fruits of Chinese magnoliavine; and wide application prospects are realized in the field ofcholestasis prevention and treatment.

The invention relates to new application of a compound, in particular to application in the preparation of a medicament for preventing and controlling lipopolysaccharide (LPS)-induced acute liver damage. A protein kinase D (PKD) inhibitor has the advantages of preventing LPS-induced mice acute liver damage, remarkably reducing the phosphorylation level of LPS-induced PKD, lowering death rate and levels of alanine aminotransferase (ALT) and aspartate transaminase (AST), improving inflammatory reaction, restraining the signal channel of LPS activated p38 mitogen-activated protein kinase (p38MAPK), lowering the level of LPS-induced tumor necrosis factor-alpha (TNK-alpha), reducing the apoptosis number of hepatic cells, the activation of caspases and the expression level of hepatic tissue adhesion molecules and lowering the activation level of myeloperoxidase (MPO).

The invention discloses a method for preparing aspartate aminotransferase and application of the aspartate aminotransferase. The method includes: modifying the coding gene sequence of humanized aspartate aminotransferase subjected to gene synthesis, and removing escherichia coli rare codons; inserting the modified aspartate aminotransferase coding gene sequence into an expression vector, and using an escherichia coli strain to transform expression; inoculating strain for transforming expression to LB (Luria-Bertani) medium for IPTG (isopropyl-beta-d-thiogalactoside) induction; and homogenizing and centrifuging obtained bacteria, and enabling the centrifuged bacteria to pass through the Ni-NTA column for purification. The method for preparing the aspartate aminotransferase is extremely simple in operation, low in preparation cost and high in finished product yield and purity; the aspartate aminotransferase has high biological activity and can be used for animal immunization and screening related antibodies by serving as antigen substances; and the method and the aspartate aminotransferase lay the foundation for establishing a badly-needed calibrator preparation platform as early as possible for domestic clinical chemistry diagnosis and developing diagnostic reagent standard substances and references.

The invention provides application of valeriana jatamansi jones or extracts thereof in the preparation of a medicine for lowering the fat and protecting the liver. The invention also provides a pharmaceutical composition for lowering the fat and protecting the liver. Animal experiments prove that the valeriana jatamansi jones or the extracts thereof has / have the functions of reducing blood fat and serum AST (aspartate transaminase), ALT (alanine transaminase), and can be used for the treatment of hyperlipidemia with definite efficacy thereby providing a new choice the clinic.